D.B. Root & Company LLC Takes Position in Stryker Corporation $SYK

Key Points

• D.B. Root & Company acquired 3,408 Stryker shares during the second quarter, valued at approximately $1.07 million. Institutional investors and hedge funds collectively own 77.09% of the company.
• Wall Street maintains a broadly positive outlook, with a “Moderate Buy” consensus rating and an average price target of $386.28, compared with shares recently trading near $330.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88, while recent insider selling remains a potential cautionary signal.

D.B. Root & Company LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,408 shares of the medical technology company's stock, valued at approximately $1,073,000.

Other large investors also recently made changes to their positions in the company. Sankala Group LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new position in shares of Stryker in the 3rd quarter worth $27,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the 4th quarter valued at $26,000. Atlas Capital Advisors Inc. bought a new stake in Stryker during the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. bought a new position in shares of Stryker in the second quarter valued at $25,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of several recent research reports. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Truist Financial boosted their price objective on Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday, May 1st. BMO Capital Markets assumed coverage on Stryker in a research report on Wednesday, July 8th. They set an "outperform" rating and a $369.00 target price on the stock. Finally, UBS Group began coverage on Stryker in a report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $386.28.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is owned by company insiders.

Stryker Stock Performance

Shares of SYK opened at $329.86 on Monday. The stock has a 50 day moving average of $326.99 and a 200 day moving average of $332.39. The company has a market capitalization of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business's revenue was up 9.4% compared to the same quarter last year. During the same period last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is currently 36.48%.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source